Improvement of osteogenic potential of biphasic calcium phosphate bone substitute coated with two concentrations of expressed recombinant human bone morphogenetic protein 2.
10.5051/jpis.2012.42.4.119
- Author:
Hyunmin CHOI
1
;
No Je PARK
;
Otgonbold JAMIYANDORJ
;
Kyung Hee CHOI
;
Min Ho HONG
;
Seunghan OH
;
Young Bum PARK
;
Sungtae KIM
Author Information
1. Department of Prosthodontics, Yonsei University College of Dentistry, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Bone morphogenetic protein 2;
Bone regeneration;
Bone substitute;
Maxillary sinus;
Rabbits
- MeSH:
Animals;
Bone Morphogenetic Protein 2;
Bone Morphogenetic Proteins;
Bone Regeneration;
Bone Substitutes;
Calcium;
Durapatite;
Escherichia coli;
Humans;
Hydroxyapatites;
Male;
Maxillary Sinus;
Membranes;
Osteogenesis;
Rabbits;
X-Ray Microtomography
- From:Journal of Periodontal & Implant Science
2012;42(4):119-126
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to determine whether biphasic calcium phosphate (BCP) bone substitute with two different concentrations of Escherichia coli-expressed recombinant human bone morphogenetic protein 2 (ErhBMP-2) enhances new bone formation in a standardized rabbit sinus model and to evaluate the concentration-dependent effect of ErhBMP-2. METHODS: Standardized, 6-mm diameter defects were made bilaterally on the maxillary sinus of 20 male New Zealand white rabbits. Following removal of the circular bony windows and reflection of the sinus membrane, BCP bone substitute without coating (control group) was applied into one defect and BCP bone substitute coated with ErhBMP-2 (experimental group) was applied into the other defect for each rabbit. The experimental group was divided into 2 subgroups according to the concentration of ErhBMP-2 (0.05 and 0.5 mg/mL). The animals were allowed to heal for either 4 or 8 weeks and sections of the augmented sinus and surrounding bone were analyzed by microcomputed tomography and histologically. RESULTS: Histologic analysis revealed signs of new bone formation in both the control and experimental groups with a statistically significant increase in bone formation in experimental group 1 (0.05 mg/mL ErhBMP-2 coating) after a 4-week healing period. However, no statistically significant difference was found between experimental group 1 and experimental group 2 (0.5 mg/mL ErhBMP-2 coating) in osteoinductive potential (P<0.05). CONCLUSIONS: ErhBMP-2 administered using a BCP matrix significantly enhanced osteoinductive potential in a standardized rabbit sinus model. A concentration-dependent response was not found in the present study.
